Phase 3 Long COVID Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent and follow the study schedule and procedures
• People aged 18 or older at the time of screening
• People who have been diagnosed with type 2 diabetes, whether through a documented medical history, a history of taking diabetes medication, or a blood sugar result (HbA1c) of 6.5% or higher at screening
• People who are already taking a medication called dapagliflozin for their diabetes, or who are willing to take dapagliflozin 10 mg daily during the study if the lead doctor considers it appropriate
• People who developed Long COVID symptoms within 3 months of getting COVID-19, and whose symptoms have lasted for at least 2 months, from a set list of recognised Long COVID symptoms
• People whose Long COVID impact score (measured by a specific tool called the LCIT) is 30 or higher at both the screening visit and the first study day
• People who test negative for an active COVID-19 infection at both the screening visit and the first study day
• Women who could become pregnant, and men who are not sterilised and whose female partners could become pregnant, who agree to use highly effective non-hormonal contraception — or remain abstinent — throughout the study and for at least 30 days after the last dose

Who may not be able to join:

• People with advanced chronic kidney disease where the kidneys are functioning at a significantly reduced level (eGFR below 25 mL/min/1.73 m²)
• People with the most severe stage of heart failure (New York Heart Association Class IV)
• People with cirrhosis of the liver, a history of liver-related brain problems, certain enlarged veins in the food pipe or stomach, active hepatitis, a history of a specific liver bypass surgery, or certain ongoing liver diseases such as primary biliary cholangitis, untreated iron overload disorder, or primary sclerosing cholangitis
• People whose blood test results at screening show certain liver enzyme levels that are too high, abnormal bilirubin levels, signs of active hepatitis B or C infection, or a history of a positive HIV test
• People taking certain medications that strongly affect how other drugs are processed in the body, or who are taking steroid medication at a dose higher than the equivalent of 10 mg of prednisone per day
• People who have received a COVID-19 vaccine or booster within the 30 days before screening
• People who have taken part in another clinical study and received an experimental medication within the 30 days before screening
• Women who are pregnant, planning to become pregnant, or currently breastfeeding, or who have a positive pregnancy test at screening or before the first study day
• People whose safety might be at risk from taking part, or who the lead investigator does not consider able or willing to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.